Literature DB >> 15994973

Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer.

Tetsuya So1, Mitsuhiro Takenoyama, Makiko Mizukami, Yoshinobu Ichiki, Masakazu Sugaya, Takeshi Hanagiri, Kenji Sugio, Kosei Yasumoto.   

Abstract

One of tumor escape mechanisms from the host's immunosurveillance system (i.e., a haplotype loss of HLA class I antigens) has been detected in various tumor cells. We hypothesize that the majority of tumor cells with normal HLA class I expression were attacked and eradicated by CTLs, and only a minority with an abnormal expression of HLA class I antigens could escape the host's immunosurveillance system. Using HLA class I-transfected tumor variants as stimulators in A904L lung cancer cell line, which has a haplotype loss of HLA class I antigens, both the transfected HLA-A26 and HLA-B39-restricted CTL lines were induced from autologous lymphocytes. However, only one HLA-B39-restricted CTL clone (CTL G3b) was established, and it was then used to identify the antigen. SGT1B [suppressor of G2 allele of SKP1 (SGT1), suppressor of kinetochore protein (SKP1)] was identified as the antigen recognized by CTL G3b. Further experiments using 13 subclones from a primary culture of A904L were found to confirm our above-mentioned hypothesis. Tumor cells with a normal HLA class I expression may thus be killed by CTL at an early stage of carcinogenesis, and only tumor cells with a haplotype loss of HLA class I antigens can escape an immune attack and develop into clinical cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15994973     DOI: 10.1158/0008-5472.CAN-04-3787

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

Review 1.  The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome.

Authors:  Romain Remark; Christian Becker; Jorge E Gomez; Diane Damotte; Marie-Caroline Dieu-Nosjean; Catherine Sautès-Fridman; Wolf-Herman Fridman; Charles A Powell; Nasser K Altorki; Miriam Merad; Sacha Gnjatic
Journal:  Am J Respir Crit Care Med       Date:  2015-02-15       Impact factor: 21.405

2.  Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure.

Authors:  Soraya Abouzahr; Georges Bismuth; Catherine Gaudin; Oliver Caroll; Peter Van Endert; Abdelali Jalil; Jean Dausset; Isabelle Vergnon; Catherine Richon; Audrey Kauffmann; Jérôme Galon; Graca Raposo; Fathia Mami-Chouaib; Salem Chouaib
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

3.  Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer.

Authors:  David S Hong; Filip Janku; Aung Naing; Gerald S Falchook; Sarina Piha-Paul; Jennifer J Wheler; Siqing Fu; Apostolia M Tsimberidou; Michael Stecher; Prasant Mohanty; John Simard; Razelle Kurzrock
Journal:  Invest New Drugs       Date:  2015-03-31       Impact factor: 3.850

4.  Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?

Authors:  Jay D Naik; Christopher J Twelves; Peter J Selby; Richard G Vile; John D Chester
Journal:  Clin Cancer Res       Date:  2011-05-16       Impact factor: 12.531

5.  Association of CD8+ T cell infiltration in oesophageal carcinoma lesions with human leucocyte antigen (HLA) class I antigen expression and survival.

Authors:  T Tsuchikawa; H Ikeda; Y Cho; M Miyamoto; T Shichinohe; S Hirano; S Kondo
Journal:  Clin Exp Immunol       Date:  2011-02-24       Impact factor: 4.330

Review 6.  ProtEx technology for the generation of novel therapeutic cancer vaccines.

Authors:  Rich-Henry Schabowsky; Rajesh K Sharma; Shravan Madireddi; Abhishek Srivastava; Esma S Yolcu; Haval Shirwan
Journal:  Exp Mol Pathol       Date:  2009-01-31       Impact factor: 3.362

Review 7.  Lung cancer-associated tumor antigens and the present status of immunotherapy against non-small-cell lung cancer.

Authors:  Kosei Yasumoto; Takeshi Hanagiri; Mitsuhiro Takenoyama
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-09-13

Review 8.  Tumor immunoediting and immunosculpting pathways to cancer progression.

Authors:  Jennifer M Reiman; Maciej Kmieciak; Masoud H Manjili; Keith L Knutson
Journal:  Semin Cancer Biol       Date:  2007-06-26       Impact factor: 15.707

9.  Clinical significance of human leukocyte antigen loss and melanoma-associated antigen 4 expression in smokers of non-small cell lung cancer patients.

Authors:  Tetsuro Baba; Hironobu Shiota; Koji Kuroda; Yoshiki Shigematsu; Yoshinobu Ichiki; Hidetaka Uramoto; Takeshi Hanagiri; Fumihiro Tanaka
Journal:  Int J Clin Oncol       Date:  2012-11-03       Impact factor: 3.402

10.  Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack.

Authors:  Gal Markel; Rachel Seidman; Yifat Cohen; Michal J Besser; Tali Cohen Sinai; Avraham J Treves; Arie Orenstein; Raanan Berger; Jacob Schachter
Journal:  Immunology       Date:  2008-06-13       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.